Interesting Image

⁶⁸Ga Prostate-specific Membrane Antigen Uptake in Metastatic Medullary Thyroid Carcinoma

10.4274/mirt.galenos.2023.47855

• Kübra Şahin
• Ali Kibar
• Cansu Güneren
• Muhammet Sait Sağer
• Kerim Sönmezoğlu

Received Date: 03.07.2023 Accepted Date: 25.09.2023 Mol Imaging Radionucl Ther 2024;33(1):54-56 PMID: 38390812

• Abstract
• Full Text
• Video - Image
• References
• 5
• 291

We present the case of a 58-year-old man with advanced medullary thyroid carcinoma who had a treatment history with different types of modalities. In the follow-up, the patient had rising calcitonin and CEA levels. Metastatic lymph nodes, liver, and bone metastases with varying degrees of uptake were detected on ¹⁸F-fluorodeoxyglucose (FDG) and ⁶⁸Ga-DOTATATE positron emission tomography/computed tomography (PET/CT). ⁶⁸Ga prostate-specific membrane antigen (PSMA) PET/CT was performed to explore whether the patient might have a chance for PSMA-targeted radionuclide therapy, and increased PSMA expression was noted in most of the metastatic lesions, even some of which have higher PSMA uptake than ¹⁸F-FDG and ⁶⁸Ga-DOTATATE.

Keywords: Medullary thyroid carcinoma, prostate-specific membrane antigen, PSMA, 18F-FDG, 68Ga-DOTA, 68Ga-PSMA

Ethics

Informed Consent: Informed consent was obtained from the patient.

Authorship Contributions

Surgical and Medical Practices: K.Ş., M.S.S., Concept: M.S.S., Design: M.S.S., K.S., Data Collection or Processing: K.Ş., A.K., C.G., Analysis or Interpretation: K.Ş., M.S.S., K.S., Literature Search: K.Ş., A.K., C.G., Writing: K.Ş., K.S.

Conflict of Interest: No conflicts of interest were declared by the authors.

Financial Disclosure: The authors declare that this study has received no financial support.

Images

1. Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, Campbell M, Dickson P, Duh QY, Ehya H, Goldner WS, Guo T, Haymart M, Holt S, Hunt JP, Iagaru A, Kandeel F, Lamonica DM, Mandel S, Markovina S, McIver B, Raeburn CD, Rezaee R, Ridge JA, Roth MY, Scheri RP, Shah JP, Sipos JA, Sippel R, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Yeh M, Cassara CJ, Darlow S. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022;20:925-951.
2. Şahin OE, Uslu-Beşli L, Asa S, Sağer S, Sönmezoğlu K. The role of ⁶⁸Ga-DOTATATE PET/CT and ¹⁸F-FDG PET/CT in the follow-up of patients with medullary thyroid cancer. Hell J Nucl Med 2020;23:321-329.
3. Liu Q, Kulkarni HR, Zhao T, Schuchardt C, Chen X, Zhu Z, Zhang J, Baum RP. Peptide receptor radionuclide therapy in patients with advanced progressive medullary thyroid cancer: efficacy, safety, and survival predictors. Clin Nucl Med 2023;48:221-227.
4. Lodewijk L, Willems SM, Dreijerink KMA, de Keizer B, van Diest PJ, Schepers A, Morreau H, Bonenkamp HJ, Van Engen-van Grunsven IACH, Kruijff S, van Hemel BM, Links TP, Nieveen van Dijkum E, van Eeden S, Valk GD, Borel Rinkes IHM, Vriens MR. The theranostic target prostate-specific membrane antigen is expressed in medullary thyroid cancer. Hum Pathol 2018;81:245-254.
5. Arora S, Prabhu M, Damle NA, Bal C, Kumar P, Nalla H, Arun Raj ST. Prostate-specific membrane antigen imaging in recurrent medullary thyroid cancer: a new theranostic tracer in the offing? Indian J Nucl Med 2018;33:261-263.
6. Arora S, Damle NA, Parida GK, Singhal A, Nalli H, Dattagupta S, Bal C. Recurrent medullary thyroid carcinoma on 68Ga-Prostate-Specific membrane antigen PET/CT: exploring new theranostic avenues. Clin Nucl Med 2018;43:359-360.
7. Hasenauer N, Higuchi T, Deschler-Baier B, Hartrampf PE, Pomper MG, Rowe SP, Fassnacht M, Buck AK, Werner RA. Visualization of tumor heterogeneity in advanced medullary thyroid carcinoma by dual-tracer molecular imaging: revealing the theranostic potential of SSTR- and PSMA-directed endoradiotherapy. Clin Nucl Med 2022;47:651-652.
8. Uijen MJM, Derks YHW, Merkx RIJ, Schilham MGM, Roosen J, Privé BM, van Lith SAM, van Herpen CML, Gotthardt M, Heskamp S, van Gemert WAM, Nagarajah J. PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. Eur J Nucl Med Mol Imaging 2021;48:4350-4368.